Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 11/20 | 0.50 |
| ▸ | TFPI | P10646 | 4/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
| ▸ | MC1R | Q01726 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351263 | 0.95 | CXCR4 (0.52) | CXCR4TFPIMC4RMC5RMC3R | |
| SCHEMBL15935518 | 0.92 | CXCR4 (0.53) | CXCR4TFPIREN | |
| SCHEMBL5580530 | 0.86 | APLNR (0.52) | APLNRTLR2 | |
| SCHEMBL10277277 | 0.77 | APLNR (0.52) | APLNR | |
| SCHEMBL15242402 | 0.75 | TLR2 (0.53) | TLR2 | |
| Ghrelin SCHEMBL29350821 | 0.74 | TFPI (0.64) | CXCR4TFPI | |
| SCHEMBL29635486 | 0.72 | CXCR4 (0.73) | CXCR4MC4RMC5RMC3RMC1R | |
| SCHEMBL29352758 | 0.72 | TLR2 (0.58) | TLR2 | |
| SCHEMBL27016689 | 0.71 | OPRD1 (0.52) | CXCR4MC4RMC5RMC3RMC1R | |
| SCHEMBL29473717 | 0.70 | CALCR (0.57) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246287-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170224813-A1 | VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF CTL | NITTO DENKO CORPORATION (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20140234377-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20140220079-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220056-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220057-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220063-A1 | VACCINE COMPOSITION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220100-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220058-A1 | VACCINE COMPOSITION FOR TRANSDERMAL OR MUCOSAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220056-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | CD4, IFNG, CD69 | CXCR4 174/4885TFPI 4137/4885MC4R 879/4885 |
| US-20140220057-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MUC1 | CXCR4 335/4885TFPI 3939/4885MC4R 576/4885 |
| US-20140220100-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | ERBB2, EGFR, ERBB3 | CXCR4 229/4885TFPI 3403/4885MC4R 1070/4885 |
| US-20170246287-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | CD4, IFNG, CD69 | CXCR4 174/4885TFPI 4137/4885MC4R 879/4885 |
| US-20140220058-A1 | VACCINE COMPOSITION FOR TRANSDERMAL OR MUCOSAL ADMINISTRATION | CD69, TSLP, MUC1 | CXCR4 788/4885TFPI 2087/4885MC4R 566/4885 |
| US-20140234377-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | TLR9, TLR3, TLR6 | CXCR4 385/4885TFPI 2905/4885MC4R 670/4885 |
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MICA | CXCR4 177/4885TFPI 3749/4885MC4R 1202/4885 |
| US-20170224813-A1 | VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF CTL | BAX, GZMB, BCL2 | CXCR4 1362/4885TFPI 2149/4885MC4R 3938/4885 |
| US-20140220079-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | MUC1, ERBB2, TLR5 | CXCR4 895/4885TFPI 4148/4885MC4R 453/4885 |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | MUC1, TAP1, MICA | CXCR4 577/4885TFPI 3967/4885MC4R 1202/4885 |
| US-20140220063-A1 | VACCINE COMPOSITION | MYD88, IRF3, CD14 | CXCR4 1887/4885TFPI 4165/4885MC4R 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.